Enasidenib clinical trials
Also written AG-221, Idhifa and CC-90007.
How each study uses enasidenib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the enasidenib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 1 Aug 2017 · IDHIFA · NDA 209606 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- Enasidenib
- 26
- CC-90007 Free Base
- 6
- Enasidenib Mesylate
- 5
- 2-Methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol Methanesulfonate
- 5
- 2-Propanol, 2-Methyl-1-((4-(6-(trifluoromethyl)-2-pyridinyl)-6-((2-(trifluoromethyl)-4-pyridinyl)amino)-1,3,5-triazin-2-yl)amino)-, Methanesulfonate (1:1)
- 5
Brand
- Idhifa
- 11
Studies by the year they started
36 studies that test it; most in 2019 (6)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 4 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 4 |
| 2019 | 6 |
| 2020 | 3 |
| 2021 | 3 |
| 2022 | 1 |
| 2023 | 3 |
| 2024 | 4 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 10 · Other 26
Celgene (9) · National Cancer Institute (NCI) (4) · Memorial Sloan Kettering Cancer Center (3) · M.D. Anderson Cancer Center (3) · City of Hope Medical Center (2) · Stichting Hemato-Oncologie voor Volwassenen Nederland (1) · Groupe Francophone des Myelodysplasies (1) · Institut de Recherches Internationales Servier (1)
Often tested with
Tested in the same studies.
Ivosidenib (6) · Venetoclax (5) · Azacitidine (4) · Daunorubicin (2) · CPX-351 (2) · Cobimetinib (2) · Cytarabine (2) · Gilteritinib (2)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 9, 1 in phase 3
Studies that test enasidenib, phase 3 first.
- Apr 2027A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive ChemotherapyPhase 3 · Stichting Hemato-Oncologie voor Volwassenen Nederland
- Jan 2027Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 MutationPhase 2 · City of Hope Medical Center
- Feb 2027Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic SyndromePhase 2 · M.D. Anderson Cancer Center
- Mar 2027Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)Phase 2 · National Cancer Institute (NCI)
- Mar 2027Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)Phase 2 · National Cancer Institute (NCI)
- Apr 2027A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)Phase 1 · Memorial Sloan Kettering Cancer Center
- Sep 2027Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene MutationPhase 2 · M.D. Anderson Cancer Center
- Sep 2027IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)Phase 2 · Alice Mims
- Nov 2027Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid LeukemiaPhase 1/2 · M.D. Anderson Cancer Center
Studies
Open first, then newest update. How each study uses enasidenib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 36
- Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)RecruitingPhase 2National Cancer Institute (NCI)NCT06577441Written as EnasidenibHow we know
- Enasidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH2A Decentralized TrialRecruitingPhase 2Washington University School of MedicineNCT06240754Written as EnasidenibHow we know
- Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)RecruitingPhase 2National Cancer Institute (NCI)NCT06672146Written as EnasidenibHow we know
- Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid LeukemiaRecruitingPhase 1/2M.D. Anderson Cancer CenterNCT04774393Written as EnasidenibHow we know
- Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base TumorsRecruitingPhase 2National Cancer Institute (NCI)NCT06176989Written as EnasidenibHow we know
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)RecruitingPhase 2National Cancer Institute (NCI)NCT05564390Written as EnasidenibHow we know
- Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene MutationRecruitingPhase 2M.D. Anderson Cancer CenterNCT03683433Written as Enasidenib MesylateHow we know
- Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic SyndromeRecruitingPhase 2M.D. Anderson Cancer CenterNCT03383575Written as EnasidenibHow we know
- Study of Biomarker-Based Treatment of Acute Myeloid LeukemiaRecruitingPhase 2/3Beat AML, LLCNCT03013998Written as AG-221 (BAML-16-001-S3)How we know
- European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory TumorsRecruitingPhase 1/2Gustave Roussy, Cancer Campus, Grand ParisNCT02813135Written as EnasidenibHow we know
- IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)RecruitingPhase 2Alice MimsNCT05401097Written as EnasidenibHow we know
- Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 MutationActive, not recruitingPhase 2City of Hope Medical CenterNCT03728335Written as Enasidenib MesylateHow we know
- A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)Active, not recruitingPhase 1Memorial Sloan Kettering Cancer CenterNCT05756777Written as EnasidenibHow we know
- A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive ChemotherapyActive, not recruitingPhase 3Stichting Hemato-Oncologie voor Volwassenen NederlandNCT03839771Written as AG-221How we know
- A Study of Enasidenib in People With T-Cell LymphomaActive, not recruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT06756308Written as EnasidenibHow we know
- IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic SyndromeActive, not recruitingPhase 2Groupe Francophone des MyelodysplasiesNCT03744390Written as AG-221How we know
- Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 MutationActive, not recruitingPhase 1Institut de Recherches Internationales ServierNCT02632708Written as AG-221How we know
- Enasidenib in Combination With Cobimetinib for the Treatment of Relapsed or Refractory Acute Myeloid LeukemiaCompletedPhase 1City of Hope Medical CenterNCT05441514Written as Enasidenib MesylateHow we know
- A Study of Enasidenib in People With Clonal Cytopenia of Undetermined SignificanceCompletedPhase 1Memorial Sloan Kettering Cancer CenterNCT05102370Written as EnasidenibHow we know
- Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 MutationActive, not recruitingPhase 2Children's Oncology GroupNCT04203316Written as EnasidenibHow we know
See all 36 studies that test enasidenib →
Given beside what is tested · 7 — enasidenib is usual care or a partner of the new treatment
- Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in RemissionRecruitingPhase 1M.D. Anderson Cancer CenterNCT05010772Written as EnasidenibHow we know
- A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction ChemotherapyActive, not recruitingPhase 1/2CelgeneNCT02677922Written as AG-221How we know
- A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative NeoplasmsWithdrawnPhase 1University of ChicagoNCT04955938Written as EnasidenibHow we know
- Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedPhase 1OHSU Knight Cancer InstituteNCT03878524Written as EnasidenibHow we know
- A Phase 1b Master Trial to Investigate CPX-351 in Subjects With Previously Untreated Acute Myeloid LeukemiaCompletedPhase 1Jazz PharmaceuticalsNCT04075747Written as EnasidenibHow we know
- Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell TransplantationWithdrawnPhase 1City of Hope Medical CenterNCT04655391Written as Enasidenib MesylateHow we know
- Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH2 Gene MutationWithdrawnPhase 2Roswell Park Cancer InstituteNCT03881735Written as EnasidenibHow we know
Codes
What other systems call enasidenib · ClinicalTrials.gg INT000407
- MeSH (NLM) C000605269enasidenibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 3T1SS4E7AGENASIDENIBConfirmed FDA, NLM, Wikidata
- RxNorm 1940332Confirmed FDA, Wikidata
- Wikidata Q27077182enasidenibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C111573EnasidenibConfirmed FDA, Wikidata
- DrugBank DB13874One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000605269 | enasidenib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 3T1SS4E7AG | ENASIDENIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1940332 | — | Confirmed FDA, Wikidata |
| Wikidata | Q27077182 | enasidenib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C111573 | Enasidenib | Confirmed FDA, Wikidata |
| DrugBank | DB13874 | — | One source Wikidata |
Also registered as enasidenib mesylate (UNII UF6PC17XAV · RxNorm 1940331).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.